FDA Brief

Warning letters Drugs

FDA warning letter to

Hubei Kangzheng Pharmaceutical Co., Ltd.

High riskIssued Nov 23, 2021Posted Jan 11, 2022Center for Drug Evaluation and Research | CDER

FDA warns Hubei Kangzheng over non-sterile ophthalmic drops, CGMP failures, and unapproved/misbranded pi yen chin.

What happened

FDA inspected the facility from June 16 to 24, 2021, and reviewed the firm’s June 28, 2021 response to the Form FDA 483 (inspection findings). FDA found pi yen chin eye drops were made as non-sterile in a Grade D area without validated sterilization, sterility testing, or particulate testing before U.S. distribution, plus stability, out-of-specification investigation, and cleaning failures. FDA also found pi yen chin was an unapproved new drug and misbranded.

What FDA found

  1. The firm lacked adequate written procedures and validation to prevent microbial contamination of an eye product labeled for ophthalmic use, and it released U.S. batches without sterility or particulate testing.

    21 CFR 211.113(b)
  2. The firm had no written stability program or data to show pi yen chin would remain acceptable through its labeled three-year expiry.

    21 CFR 211.166(a)
  3. The firm did not investigate an active ingredient infrared spectrum mismatch or unknown peaks in finished product batches, including a batch distributed to the U.S.

    21 CFR 211.192
  4. Cleaning validation was inadequate, non-sterile reusable wipes were used, and rust and a fraying conveyor belt were found on product-contact equipment.

    21 CFR 211.67(a)
  5. Pi yen chin is an unapproved new drug because it contains naphazoline HCl 0.1%, above the 0.01% to 0.03% allowed in the OTC ophthalmic monograph, and has no FDA-approved application.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  6. The product is misbranded because the label lacks a complete U.S. address or phone number for serious adverse event reports and does not comply with section 505G marketing requirements.

    FD&C Act sections 502(x) and 502(ee), 21 U.S.C. 352(x) and 352(ee)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions or a delay schedule. It also asks the firm to clarify whether it will resume U.S. drug manufacturing and to notify FDA before resuming.

Who should pay attention

  • U.S. distributors and retailers that sold or stocked pi yen chin eye drops
  • companies using Hubei Kangzheng as a contract manufacturer or supplier
  • quality teams managing ophthalmic OTC drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk